Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?
about
Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender DifferencesBone Mineral Density in Schizophrenia: An Update of Current Meta-Analysis and Literature Review Under Guideline of PRISMAChronic Psychosocial Stress Impairs Bone Homeostasis: A Study in the Social Isolation Reared Rat.Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial.Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients.Bone mass in schizophrenia and normal populations across different decades of lifeRisk of osteoporosis and fracture incidence in patients on antipsychotic medication.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Psychotropic medication use in anorexia nervosa between 1997 and 2009.Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).Effects of long-term combination treatment with valproate and atypical antipsychotics on bone mineral density and bone metabolism in premenopausal patients with bipolar disorder: a preliminary studyThe Role of Parathyroid Hormone-Related Protein (PTHrP) in Osteoblast Response to Microgravity: Mechanistic Implications for Osteoporosis Development.The Effects of Chlorpromazine on Reproductive System and Function in Female Rats.The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disordersOsteoporosis and fracture risk in people with schizophreniaFactors associated with decreased bone mineral density in postmenopausal women with schizophrenia.Bone density characteristics and major depressive disorder in adolescentsOsteoporosis associated with antipsychotic treatment in schizophreniaIs antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications.Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment.A review of the association between antipsychotic use and hyperprolactinaemia.Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.Antipsychotic use and the risk of hip/femur fracture: a population-based case-control studyA well-being programme in severe mental illness. Baseline findings in a UK cohort.Sex-specific differences in side effects of psychotropic drugs: genes or gender?The Effects of Prolactin-Raising and Prolactin-Sparing Antipsychotics on Prolactin Levels and Bone Mineral Density in Schizophrenic Patients.Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management.Antipsychotic-induced hyperprolactinaemia.A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia.Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.No association between bone mass and prolactin levels among patients with schizophrenia.9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder.Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis.Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.High bone turnover but normal bone mineral density in women suffering from schizophrenia.Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics.Change in sexual dysfunction with aripiprazole: a switching or add-on study.Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone.
P2860
Q26739664-718A0D5E-7EA0-4ECE-83D7-65F77B371054Q26775158-A6E57022-1507-4CD4-987E-6E8480BFB8D5Q30380187-32189F70-791A-49D4-B547-D2623387D2B0Q30490025-2C44F2A2-A024-4CC5-8D08-62AB39AAF69FQ30493532-9C13E305-3457-4F60-81AC-8D7D712A0CBFQ33396837-9013F24F-2195-457C-B10D-736C0F31FC6FQ34026011-BC26E40C-F4EB-48F8-86C7-0367016137ADQ34623350-6ABE66C7-9D2F-4D1D-A1EC-4B0DDEF6871EQ34639626-46AE2C88-E0E2-4093-BDFD-03E5310D70F2Q34966395-D455B42F-27DB-441A-BF0A-224B9FAA94C3Q35238351-8CD057C2-602C-45B8-99D3-6BB1A0E3A74FQ36087241-E8306C5F-B163-4500-B290-5FCA006B7ED3Q36351299-F34523D1-B45D-479F-8626-BF58ED09805DQ36570221-9AE7AD1B-A970-4F88-9D33-E2FA73252A31Q36592205-2D97DE33-3ED1-4E47-A65C-03F0210AFB3BQ36603968-2A9E6034-1B05-49B1-9554-BB16FD7C13D1Q36605266-C8499730-B67E-4D5B-9ABB-1338B1DB3565Q36838238-B4A691EB-3308-4A71-BB05-36C8DAFDB6F0Q37064780-F2ADCB76-75E9-4C94-802B-FDEBC3DA0028Q37078982-165D6946-02D2-43DB-90B2-6CC699A2AC7FQ37162798-122F669D-684C-4615-91A4-8F395B80EBC0Q37162808-9D810DD7-C24C-4D9A-8DFF-E5514509DF78Q37308723-97C9745B-6EB3-4214-B733-E1F3D91D9291Q37427322-4E6D7320-692D-4783-9FF8-6310AEFBB18EQ37598900-9282C21F-C487-4F73-AEC0-A66FC6FF5D34Q37703953-A6BED1D2-1518-4DA5-AA45-B2CB782128DFQ37747570-C4B397B8-F25B-4A95-A36C-186EF8179DCFQ37895702-7D3C00BB-27FF-450F-ABDC-4FC7712D9F9EQ38231654-77FF82B4-AF6B-495D-BE4E-9313BE92867CQ38778145-86F4A81A-F97E-4719-826E-67C095C50A4FQ39684311-F918AB78-CC06-4B75-BCD2-17CBB4F533C1Q39995440-9FA19F97-9523-48A6-A264-A725A5A56242Q42266503-BC6801E1-1F22-47F5-BA61-A0E7BA07E73DQ44212820-14E8453B-4D3B-4A7E-B29D-BD587DF79AF0Q46110645-322A4E65-52FC-4A70-95EA-FB6C18FBA54AQ46351516-8A80E85A-A1F0-40C0-A2DD-243D2F71485DQ46597827-35CF6247-2818-40A9-BE14-DB4A5094E5A9Q46727015-2E7135FE-E4C4-4FEF-A1B8-B6E11F3DBAD2Q47350555-4D744412-C453-46DB-BF68-2830017EB6F9
P2860
Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Antipsychotic drugs: a new ris ...... oung women with schizophrenia?
@ast
Antipsychotic drugs: a new ris ...... oung women with schizophrenia?
@en
Antipsychotic drugs: a new ris ...... oung women with schizophrenia?
@nl
type
label
Antipsychotic drugs: a new ris ...... oung women with schizophrenia?
@ast
Antipsychotic drugs: a new ris ...... oung women with schizophrenia?
@en
Antipsychotic drugs: a new ris ...... oung women with schizophrenia?
@nl
prefLabel
Antipsychotic drugs: a new ris ...... oung women with schizophrenia?
@ast
Antipsychotic drugs: a new ris ...... oung women with schizophrenia?
@en
Antipsychotic drugs: a new ris ...... oung women with schizophrenia?
@nl
P921
P1476
Antipsychotic drugs: a new ris ...... oung women with schizophrenia?
@en
P2093
Anna Maria Meaney
P356
10.1097/01.JCP.0000150223.31007.E0
P407
P577
2005-02-01T00:00:00Z